PULMOPHARMA ApS Financials, key figures and credit report
Gross profit -49.4 kDKK FY 2025 -140.8% vs 2024
EBIT -49.4 kDKK FY 2025 -140.8% vs 2024
Net debt -1 120.9 kDKK FY 2025 -181.6% vs 2024
Quick ratio 1.8 FY 2025 +0.7 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -80.38 | -56.50 | -47.30 | -20.50 | -49.35 |
| EBIT | -80.38 | -56.50 | -47.30 | -20.50 | -49.35 |
| Other financial expenses | -12.72 | -6.33 | |||
| Pre-tax profit | -93.10 | -62.83 | -47.30 | -20.50 | -49.35 |
| Net earnings | -93.10 | -62.83 | -47.30 | -20.50 | -49.35 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Development expenditure | 882.53 | 3 965.16 | 5 173.24 | 7 198.67 | 9 775.35 |
| Intangible assets total | 882.53 | 3 965.16 | 5 173.24 | 7 198.67 | 9 775.35 |
| Tangible assets total | |||||
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Prepayments and accrued income | 1 598.01 | 887.78 | 177.56 | 2 090.25 | 1 281.12 |
| Current other receivables | 96.38 | 81.66 | 44.38 | 19.98 | 14.48 |
| Short term receivables total | 1 694.39 | 969.44 | 221.93 | 2 110.23 | 1 295.60 |
| Cash and bank deposits | 1 409.60 | 18.87 | 3 501.22 | 16.98 | 2 510.84 |
| Cash and cash equivalents | 1 409.60 | 18.87 | 3 501.22 | 16.98 | 2 510.84 |
| Balance sheet total (assets) | 3 986.52 | 4 953.47 | 8 896.39 | 9 325.89 | 13 581.79 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 40.00 | 40.00 | 46.67 | 46.67 | 47.95 |
| Share premium account | 3 963.00 | 3 963.00 | 7 956.33 | 7 956.33 | 12 060.25 |
| Retained earnings | - 398.18 | - 491.29 | - 554.12 | - 601.41 | - 621.91 |
| Profit of the financial year | -93.10 | -62.83 | -47.30 | -20.50 | -49.35 |
| Shareholders equity total | 3 511.72 | 3 448.89 | 7 401.59 | 7 381.09 | 11 436.93 |
| Non-current liabilities total | |||||
| Current trade creditors | 7.37 | 14.70 | 4.92 | 4.92 | 4.92 |
| Current owed to participating | 467.44 | 1 039.89 | 1 039.89 | 1 389.89 | 1 389.89 |
| Other non-interest bearing current liabilities | 450.00 | 450.00 | 550.00 | 750.05 | |
| Current liabilities total | 474.80 | 1 504.58 | 1 494.80 | 1 944.80 | 2 144.85 |
| Balance sheet total (liabilities) | 3 986.52 | 4 953.47 | 8 896.39 | 9 325.89 | 13 581.79 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated